Elite controllers and long-term nonprogressors: Models for HIV vaccine development?

Journal of AIDS and Clinical Research

Volumn 3, Issue SPL ISSUE8, 2012, Pages

  Okulicz, Jason F ^a,b  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879806870     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.S8-005     Document Type: Editorial

References (50)

1. Okulicz JF, Marconi VC, Landrum ML, Wegner S, Weintrob A, et al. (2009) Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 200: 1714-1723.
2. Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, et al. (2009) Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 23: 1163-1169.
3. Madec Y, Boufassa F, Avettand-Fenoel V, Hendou S, Melard A, et al. (2009) Early control of HIV-1 infection in long-term nonprogressors followed since diagnosis in the ANRS SEROCO/HEMOCO cohort. J Acquir Immune Deic Syndr 50: 19-26.
4. Munoz A, Kirby AJ, He YD, Margolick JB, Visscher BR, et al. (1995) Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. J Acquir Immune Deic Syndr Hum Retrovirol 8: 496-505.
5. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W (1993) The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 7: 1159-1166.
6. Lefrere JJ, Morand-Joubert L, Mariotti M, Bludau H, Burghoffer B, et al. (1997) Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeiciency virus infection 90: 1133-1140.
7. O'Brien TR, Blattner WA, Waters D, Eyster E, Hilgartner MW, et al. (1996) Page 3 of 4 Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 276: 105-110.
8. Rodes B, Toro C, Paxinos E, Poveda E, Martinez-Padial M, et al. (2004) Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. AIDS 18: 1109-1116.
9. Deeks SG, Walker BD (2007) Human immunodeiciency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27: 406-416.
10. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, et al. (2008) Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 197: 563-571.
11. Riedel DJ, Sajadi MM, Armstrong CL, Cummings JS, Cairo C, et al. (2009) Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells. AIDS 23: 1955-1964.
12. Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, et al. (2005) HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 41: 1053-1056.
13. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, et al. (1995) Studies in subjects with long-term nonprogressive human immunodeiciency virus infection. N Engl J Med 332: 209-216.
14. Strathdee SA, Veugelers PJ, Page-Shafer KA, McNulty A, Moss AR, et al. (1996) Lack of consistency between ive deinitions of nonprogression in cohorts of HIV-infected seroconverters. AIDS 10: 959-965.
15. Buchbinder S, Vittinghoff E (1999) HIV-infected long-term nonprogressors: epidemiology, mechanisms of delayed progression, and clinical and research implications. Microbes Infect 1: 1113-1120.
16. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321-333.
17. Hunt PW, Landay AL, Sinclair E, Martinson JA, Hatano H, et al. (2011) A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One 6: e15924.
18. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, et al. (2007) Isolation and characterization of replication-competent human immunodeiciency virus type 1 from a subset of elite suppressors. J Virol 81: 2508-2518.
19. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al. (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13: 46-53.
20. Pereyra F, Palmer S, Miura T, Block BL, Wiegand A, et al. (2009) Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis 200: 984-990.
21. Boufassa F, Saez-Cirion A, Lechenadec J, Zucman D, Avettand-Fenoel V, et al. (2011) CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory. PLoS One 6: e18726.
22. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
23. Okulicz JF, Grandits GA, Weintrob AC, Landrum ML, Ganesan A, et al. (2010) CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy. Clin Infect Dis 50: 1187-1191.
24. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, et al. (2008) Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 197: 126-133.
25. Phillips AN, Neaton J, Lundgren JD (2008) The role of HIV in serious diseases other than AIDS. AIDS 22: 2409-2418.
26. Kamya P, Tsoukas CM, Boulet S, Routy JP, Thomas R, et al. (2011) T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers. AIDS Res Ther 8: 20.
27. Dolan MJ, Kulkarni H, Camargo JF, He W, Smith A, et al. (2007) CCL3L1 and CCR5 inluence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol 8: 1324-1336.
28. Mudd PA, Ericsen AJ, Price AA, Wilson NA, Reimann KA, et al. (2011) Reduction of CD4+ T cells in vivo does not affect virus load in macaque elite controllers. J Virol 85: 7454-7459.
29. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, et al. (2000) HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 97: 2709-2714.
30. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, et al. (2010) The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330: 1551-1557.
31. Han Y, Lai J, Barditch-Crovo P, Gallant JE, Williams TM, et al. (2008) The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. Aids 22: 541-544.
32. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, et al. (1999) HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283: 1748-1752.
33. Kaslow RA, Carrington M, Apple R, Park L, Muñoz A, et al. (1996) Inluence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 2: 405-411.
34. Magierowska M, Theodorou I, Debre P, Sanson F, Autran B, et al. (1999) Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeiciency virus-1-infected individuals. Blood 93: 936-941.
35. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, et al. (2007) Superior control of HIV-1 replication by CD8+ T cells is relected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204: 2473-2485.
36. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, et al. (2007) HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 104: 6776-6781.
37. Xie J, Lu W, Samri A, Costagliola D, Schnuriger A, et al. (2010) Distinct differentiation proiles of HIV-Gag and Nef-speciic central memory CD8+ T cells associated with HLA-B57/5801 and virus control. Aids 24: 2323-2329.
38. Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, et al. (2008) Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29: 1009-1021.
39. Almeida JR, Sauce D, Price DA, Papagno L, Shin SY, et al. (2009) Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIVsuppressive activity. Blood 113: 6351-6360.
40. Saez-Cirion A, Sinet M, Shin SY, Urrutia A, Versmisse P, et al. (2009) Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-speciic CD8 T cell responses. J Immunol 182: 7828-7837.
41. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, et al. (2007) Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/ HLA subtypes. J Exp Med 204: 3027-3036.
42. Alter G, Rihn S, Walter K, Nolting A, Martin M, et al. (2009) HLA class I subtypedependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeiciency virus type 1 infection. J Virol 83: 6798-6805.
43. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, et al. (2007) Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 39: 733-740.
44. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, et al. (2009) Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. Aids 23: 897-906.
45. Bailey JR, Lassen KG, Yang HC, Quinn TC, Ray SC, et al. (2006) Neutralizing antibodies do not mediate suppression of human immunodeiciency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 80: 4758-4770.
46. Braibant M, Brunet S, Costagliola D, Rouzioux C, Agut H, et al. (2006) Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. Aids 20: 1923-1930.
47. Ngo-Giang-Huong N, Candotti D, Goubar A, Autran B, Maynart M, et al. (2001) HIV type 1-speciic IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res Hum Retroviruses 17: 1435-1446.
48. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, et al. (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIVinfected individuals. Nature 458: 636-640.
49. Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, et al. (2009) Frequency and phenotype of human immunodeiciency virus envelope-speciic B cells from patients with broadly cross-neutralizing antibodies. J Virol 83: 188-199.
50. Migueles SA, Connors M (2010) Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. JAMA 304: 194-201.